news
Novel nasal spray effectively prevents influenza infection
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
List view / Grid view
Influenza
news
New two-step vaccination strategy for influenza
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
news
Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
article
Recce Pharmaceuticals’ synthetic approach to combatting AMR
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
news
New trivalent vaccine for clade 1 sarbecoviruses
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
news
Identification of antibodies to target the NA globular head domain
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
news
Development of a new recombinant flu vaccine
A new vaccine, based on a nanoliposome that promotes proteins to be displayed on its surface, results in potent vaccine efficacy.
news
Microbiota composition influences respiratory virus susceptibility
The interactions linking intestinal microbiota with the functionality of basally resident alveolar macrophages and severity of infection are revealed.
news
Novel class of antibodies can neutralise multiple strains of flu virus
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
news
Immune cells predict flu symptoms
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
news
Cracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
news
Novel nasal vaccine strategy could improve COVID-19 protection
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
news
Study finds protein H84T-BanLec is effective against all known coronaviruses and influenzas
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
article
Advancing vaccines with extracellular vesicles
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
news
Janssen licenses its pan-influenza antibody to Leyden Labs
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.